The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 15 July 2002. doi:10.1084/jem.20020029
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 115K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ford, M. S.
Right arrow Articles by Zhang, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, M. S.
Right arrow Articles by Zhang, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2002/7/261/ $5.00
The Journal of Experimental Medicine, Volume 196, Number 2, July 15, 2002 261-267


Brief Definitive Report

The Immune Regulatory Function of Lymphoproliferative Double Negative T Cells In Vitro and In Vivo

Megan S. Ford1, Kevin J. Young1, Zhuxu Zhang1, Pamela S. Ohashi2 and Li Zhang1

1 Department of Laboratory Medicine and Pathobiology and Department of Immunology, University of Toronto, Multi Organ Transplantation Program, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario M5G 2C4, Canada
2 Department of Medical Biophysics and Immunology, University of Toronto, Ontario Cancer Institute, University Health Network, Toronto, Ontario M5G 2M9, Canada

Address correspondence to Li Zhang, Toronto General Hospital Research Institute, Department of Laboratory Medicine and Pathobiology, CCRW 2-809, 101 College Street, Toronto, Ontario M5G 2C4, Canada. Phone: 416-340-4915; Fax: 416-597-9749; E-mail: lzhang{at}transplantunit.org

Lymphoproliferative (lpr) mice, which lack functional Fas receptor expression and develop autoimmune lymphoproliferative disease, have an accumulation of T cell receptor-{alpha}ß+CD4-CD8- (double negative T cells [DNTC]) in the periphery. The function of the accumulating DNTC is not clear. In this study we demonstrate that B6/lpr DNTC can dose dependently kill syngeneic CD8+ and CD4+ T cells from wild-type B6 mice through Fas/Fas ligand interactions in vitro. We also demonstrate that B6/lpr DNTC that are activated and expand in vivo are able to specifically down-regulate allogeneic immune responses mediated by syngeneic Fas+CD4+ and CD8+ T cells in vivo. B6/lpr DNTC that have been preactivated in vivo by infusion of either class I– (bm1) or class II– (bm12) mismatched allogeneic lymphocytes are able to specifically enhance the survival of bm1 or bm12, but not third-party skin allografts when adoptively transferred into naive B6+/+ mice. These findings clearly demonstrate that B6/lpr DNTC have a potent immune regulatory function in vitro and in vivo. They also provide new insights into the mechanisms involved in the development of autoimmune disease in lpr mice.

Key Words: autoimmune • transplantation • immune tolerance • suppressor T lymphocytes • Fas ligand


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS